Latest market price
1.44
+0.02+1.41%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -0.15 | Insider Own | — | Shs Outstand | 444.96M | Perf Week | -0.69% |
| Market Cap | 640.74M | Forward P/E | — | EPS next Y | -0.21 | Insider Trans | 0.00% | Shs Float | 218.98M | Perf Month | -20.88% |
| Enterprise Value | 506.74M | PEG | — | EPS next Q | -0.06 | Short Float | 12.19% | Perf Quarter | -42.17% | ||
| Income | -62.00M | P/S | 15.63 | EPS this Y | — | Short Ratio | 9.35 | Perf Half Y | -10.00% | ||
| Sales | 41.00M | P/B | 3.66 | EPS next Y | — | ROA | -24.44% | Short Interest | 26.70M | Perf YTD | 25.22% |
| Book/sh | 0.39 | P/C | 3.35 | EPS next 5Y | — | ROE | -40.40% | 52W High | 2.68 -46.27% | Perf Year | 7.46% |
| Cash/sh | 0.43 | P/FCF | — | EPS past 3/5Y | — | ROIC | -23.00% | 52W Low | 1.10 30.91% | Perf 3Y | 25.22% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — 15.81% | Gross Margin | 98.85% | Volatility | 5.03% 5.22% | Perf 5Y | -72.36% |
| Dividend TTM | — | EV/Sales | 12.36 | EPS Y/Y TTM | — | Oper. Margin | -131.43% | ATR (14) | 0.09 | Perf 10Y | -91.02% |
| Dividend Ex-Date | — | Quick Ratio | 13.29 | Sales Y/Y TTM | -30.51% | Profit Margin | -147.38% | RSI (14) | 31.52 | Recom | 2.79 |
| Dividend Gr. 3/5Y | — | Current Ratio | 13.37 | EPS Q/Q | — | SMA20 | -8.10% | Beta | 1.06 | Target Price | — |
| Payout | 0.00% | Debt/Eq | 0.33 | Sales Q/Q | -96.55% | SMA50 | -23.06% | Rel Volume | 0.75 | Prev Close | 1.42 |
| Employees | 81 | LT Debt/Eq | 0.33 | Earnings | Nov 05 | SMA200 | -23.63% | Avg Volume | 2.69M | Price | 1.44 |
| IPO Date | Apr 07, 2000 | Option/Short | No / Yes | EPS/Sales Surpr. | -104.64% -82.66% | Net Debt/EBITDA | — | Volume | 2,020,696 | Change | 1.41% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Mar-12-26 | Reiterated | H.C. Wainwright | Buy | |
| Mar-04-25 | Downgrade | Leerink Partners | Outperform → Market Perform | |
| Oct-18-24 | Reiterated | Leerink Partners | ||
| Jan-29-21 | Downgrade | Wedbush | Outperform → Neutral | |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral | |
| Dec-08-20 | Upgrade | Citigroup | Neutral → Buy | |
| Nov-18-20 | Upgrade | Gabelli & Co. | Hold → Buy | |
| Dec-11-19 | Downgrade | Gabelli & Co. | Buy → Hold | |
| Nov-08-19 | Downgrade | Citigroup | Buy → Neutral | |
| Sep-11-19 | Upgrade | Gabelli & Co. | Hold → Buy |
Latest News· Times ET
Oct-29-26
Oct-29-2608:30AM
Oct-23-26
Oct-23-2608:30AM
Oct-21-26
Oct-21-2608:30AM
Oct-07-26
Oct-07-2608:21AM
Oct-05-26
Oct-02-26
Oct-02-2601:10AM
Sep-30-26
Sep-30-2602:38PM
Sep-28-26
08:46AM
04:34AM
Sep-21-26
Sep-21-2605:03AM
Sep-16-26
Sep-16-2604:01AM
Sep-09-26
Sep-09-2604:57PM
Sep-01-26
Sep-01-2604:05PM
Company
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 41 | 50 | 31 | 1 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 1 | 59 | — | — | — | — | — | |
| Gross Profit | 41 | 50 | 30 | -58 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 36 | 37 | 132 | 0 | — | — | — | — | — | |
| Research and Development | 60 | 61 | 84 | 59 | — | — | — | — | — | |
| Other Operating Expense | -1 | 0 | 12 | 55 | — | — | — | — | — | |
| Operating Income | -55 | -49 | -197 | -172 | — | — | — | — | — | |
| Interest Expense | 9 | 8 | 16 | 13 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 2 | 7 | 12 | 8 | — | — | — | — | — | |
| Net Income Before Taxes | -62 | -50 | -200 | -177 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -62 | -50 | -200 | -177 | — | — | — | — | — | |
| Net Income From Continuing Operations | -62 | -50 | -200 | -177 | — | — | — | — | — | |
| Net Income | -62 | -50 | -200 | -177 | — | — | — | — | — | |
| EPS (Recurring) | -0.15 | -0.14 | -0.63 | -0.80 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.15 | -0.14 | -0.63 | -0.80 | — | — | — | — | — | |
| EPS (Diluted) | -0.15 | -0.14 | -0.63 | -0.80 | — | — | — | — | — | |
| EBITDA | -51 | -41 | -184 | -170 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 15.38 | 8.35 | 7.62 | 338.13 | — | — | — | — | — | |
| Gross Margin | 100.00 | 100.00 | 96.77 | -5,800.00 | — | — | — | — | — | |
| Operating Margin | -134.15 | -98.00 | -635.48 | -17,200.00 | — | — | — | — | — | |
| Net Margin | -151.22 | -100.00 | -645.16 | -17,700.00 | — | — | — | — | — | |
| Shares Outstanding | 438 | 363 | 320 | 221 | — | — | — | — | — | |
| Market Capitalization | 631 | 417 | 236 | 338 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Swain Judith L | Director | Jun 03 '26 | Option Exercise | 0.00 | 89,312 | 0 | 174,486 | Jun 04 |
| Sullivan Diane E. | Director | Jun 03 '26 | Option Exercise | 0.00 | 89,312 | 0 | 126,122 | Jun 04 |
| SOBECKI CHRISTOPHER J | Director | Jun 03 '26 | Option Exercise | 0.00 | 89,312 | 0 | 293,177 | Jun 04 |
| Cheung Ivan | Director | Jun 03 '26 | Option Exercise | 0.00 | 89,312 | 0 | 89,312 | Jun 04 |
| BARKER SAM L | Director | Jun 03 '26 | Option Exercise | 0.00 | 89,312 | 0 | 213,771 | Jun 04 |
| Amouyal Philippe | Director | Jun 03 '26 | Option Exercise | 0.00 | 89,312 | 0 | 374,486 | Jun 04 |
| DEBBANE RAYMOND | Director | Jun 03 '26 | Option Exercise | 0.00 | 89,312 | 0 | 1,995,498 | Jun 04 |
| Artal Participations S.a r.l. | Director, 10% Owner | Apr 30 '26 | Option Exercise | 0.00 | 20,830,170 | 0 | 175,156,062 | May 08 |
| McDermott Wendy | SVP, Human Resources | Feb 28 '26 | Option Exercise | 0.00 | 224,406 | 0 | 346,052 | Mar 03 |
| Martens Rachel Yap | SVP, Partnerships & Corp Strat | Feb 28 '26 | Option Exercise | 0.00 | 67,090 | 0 | 67,090 | Mar 03 |
| Granowitz Craig B | SVP, Chief Medical Officer | Feb 28 '26 | Option Exercise | 0.00 | 312,276 | 0 | 432,528 | Mar 03 |
| Gopinathan Suma | SVP, Discovery | Feb 28 '26 | Option Exercise | 0.00 | 99,950 | 0 | 174,470 | Mar 03 |
| DeFrancesco Lisa | SVP, IR and Corp Comm | Feb 28 '26 | Option Exercise | 0.00 | 152,864 | 0 | 168,441 | Mar 03 |
| Crum Brian T | SVP, General Counsel & Secr. | Feb 28 '26 | Option Exercise | 0.00 | 273,006 | 0 | 533,821 | Mar 03 |
| Coiante Scott M | SVP, Chief Financial Officer | Feb 28 '26 | Option Exercise | 0.00 | 160,237 | 0 | 160,237 | Mar 03 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.